These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

138 related items for PubMed ID: 38809346

  • 21. Early preablation rhTSH-stimulated thyroglobulin predicts outcome of differentiated thyroid cancer (DTC) patients.
    Campennì A, Ruggeri RM, Siracusa M, Comis AD, Romano D, Vento A, Lanzafame H, Capoccetti F, Alibrandi A, Baldari S, Giovanella L.
    Eur J Nucl Med Mol Imaging; 2021 Jul; 48(8):2466-2475. PubMed ID: 33416957
    [Abstract] [Full Text] [Related]

  • 22. Evaluating the prognostic factors associated with cancer-specific survival of differentiated thyroid carcinoma presenting with distant metastasis.
    Lang BH, Wong KP, Cheung CY, Wan KY, Lo CY.
    Ann Surg Oncol; 2013 Apr; 20(4):1329-35. PubMed ID: 23104708
    [Abstract] [Full Text] [Related]

  • 23. Impact on overall survival of radioactive iodine in low-risk differentiated thyroid cancer patients.
    Schvartz C, Bonnetain F, Dabakuyo S, Gauthier M, Cueff A, Fieffé S, Pochart JM, Cochet I, Crevisy E, Dalac A, Papathanassiou D, Toubeau M.
    J Clin Endocrinol Metab; 2012 May; 97(5):1526-35. PubMed ID: 22344193
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Stimulated thyroglobulin and pre-ablation antithyroglobulin antibody products can predict the response to radioiodine therapy of TgAb-positive differentiated thyroid cancer patients: a retrospective study.
    Han N, Lu C, Li J, Wang C, Zhao Z, Zhang Y, Liu X, Si Z, Wang G, Wang Z, Li F, Wang X.
    Front Endocrinol (Lausanne); 2023 May; 14():1222470. PubMed ID: 37810895
    [Abstract] [Full Text] [Related]

  • 26. European Perspective on 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: Proceedings of an Interactive International Symposium.
    Luster M, Aktolun C, Amendoeira I, Barczyński M, Bible KC, Duntas LH, Elisei R, Handkiewicz-Junak D, Hoffmann M, Jarząb B, Leenhardt L, Musholt TJ, Newbold K, Nixon IJ, Smit J, Sobrinho-Simões M, Sosa JA, Tuttle RM, Verburg FA, Wartofsky L, Führer D.
    Thyroid; 2019 Jan; 29(1):7-26. PubMed ID: 30484394
    [Abstract] [Full Text] [Related]

  • 27. Second radioiodine treatment in patients with differentiated thyroid carcinoma: Causes and effects.
    Sicilia Pozo MLN, Pena Pardo FJ, Amo Salas M, Cruz Montijano M, Torres Hernández J, Padilla Bermejo A, Montalbán Méndez C, Zhao Montero M, Soriano Castrejón Á, García Vicente AM.
    Endocrinol Diabetes Nutr (Engl Ed); 2024 Jan; 71(1):4-11. PubMed ID: 38388076
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. A comparative analysis of treatment efficacy in intermediate-risk thyroid cancer.
    Abiri A, Nguyen T, Goshtasbi K, Torabi SJ, Kuan EC, Armstrong WB, Tjoa T, Haidar YM.
    Eur Arch Otorhinolaryngol; 2023 May; 280(5):2525-2533. PubMed ID: 36651960
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. The Positive Lymph Node Number and Postoperative N-Staging Used to Estimate Survival in Patients with Differentiated Thyroid Cancer: Results from the Surveillance, Epidemiology, and End Results Dataset (1988-2008).
    Wei WJ, Lu ZW, Wen D, Liao T, Li DS, Wang Y, Zhu YX, Wang ZY, Wu Y, Wang YL, Ji QH.
    World J Surg; 2018 Jun; 42(6):1762-1771. PubMed ID: 29185020
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. TIMING OF RADIOACTIVE IODINE THERAPY DOES NOT IMPACT OVERALL SURVIVAL IN HIGH-RISK PAPILLARY THYROID CARCINOMA.
    Suman P, Wang CH, Abadin SS, Block R, Raghavan V, Moo-Young TA, Prinz RA, Winchester DJ.
    Endocr Pract; 2016 Jul; 22(7):822-31. PubMed ID: 27018620
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Factors Influencing the Success of the First Radioiodine Therapy for Differentiated Thyroid Carcinoma.
    Claimon A, Pusuwan P, Khiewvan B.
    J Med Assoc Thai; 2017 Feb; 100(2):207-18. PubMed ID: 29916638
    [Abstract] [Full Text] [Related]

  • 38. Concordance in postsurgical radioactive iodine therapy recommendations between Watson for Oncology and clinical practice in patients with differentiated thyroid carcinoma.
    Kim M, Kim BH, Kim JM, Kim EH, Kim K, Pak K, Jeon YK, Kim SS, Park H, Kang T, Lee BJ, Kim IJ.
    Cancer; 2019 Aug 15; 125(16):2803-2809. PubMed ID: 31216369
    [Abstract] [Full Text] [Related]

  • 39. Comparison of Survival Outcomes Following Postsurgical Radioactive Iodine Versus External Beam Radiation in Stage IV Differentiated Thyroid Carcinoma.
    Yang Z, Flores J, Katz S, Nathan CA, Mehta V.
    Thyroid; 2017 Jul 15; 27(7):944-952. PubMed ID: 28446057
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.